CD86 and neoplasm: Although all mice immunized with LEX-CD8086 more obviously reduced tumor burden than LEX-null and PBS did, none showed long-term survival, suggesting that the upregulation of CD80 and CD86 expression alone in LEX-based vaccines may still not be sufficient to inhibit leukemia progression.